Stock Performance and Market Context
The stock has experienced a notable decline over the past two trading sessions, shedding approximately 22.99% in returns during this period. On the day it hit the new low, the share price fell by 7.80%, underperforming its sector by 1.48%. Intraday volatility was elevated at 9.78%, reflecting heightened trading activity and uncertainty. The stock’s intraday range was wide, touching a high of Rs.121.85 before retreating to the low of Rs.104.85.
Indo US Bio-Tech is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained downward momentum. This contrasts with the broader Agriculture sector, which itself has declined by 5.3% on the day, indicating sector-wide pressures.
Meanwhile, the benchmark Sensex opened sharply lower by 1,862.15 points but recovered some ground to trade at 77,611.01, still down 1.66% for the day. The Sensex has been on a three-week losing streak, falling 6.28% over that period, with volatility indices such as INDIA VIX reaching new 52-week highs, underscoring elevated market nervousness.
Financial Performance and Ratings
Indo US Bio-Tech’s financial metrics reveal challenges in both recent quarters and over the longer term. The company reported its lowest quarterly net sales at Rs.22.80 crores and a PBDIT of Rs.4.15 crores, reflecting subdued revenue and earnings generation. The latest six-month PAT stood at Rs.6.45 crores, representing a decline of 31.46% compared to previous periods.
Over the past year, the stock has delivered a negative return of 44.14%, significantly underperforming the Sensex, which gained 4.50% in the same timeframe. The company’s operating profit growth rate over the last five years has been a modest 19.07% annually, which has not translated into sustained share price appreciation.
Reflecting these trends, the company’s Mojo Score stands at 41.0 with a Mojo Grade of Sell, downgraded from Hold on 19 Jan 2026. The market capitalisation grade is rated 4, indicating a relatively smaller market cap within its peer group.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Valuation and Efficiency Metrics
Despite recent price weakness, Indo US Bio-Tech exhibits some positive financial characteristics. The company maintains a high return on capital employed (ROCE) of 27.98%, indicating efficient use of capital in generating profits. Its debt servicing capability is strong, with a low Debt to EBITDA ratio of 0.91 times, suggesting manageable leverage levels.
The stock’s valuation metrics also indicate an attractive profile relative to peers. With a ROCE of 16.4% and an enterprise value to capital employed ratio of 2.2, the company is trading at a discount compared to historical peer averages. Over the past year, while the stock price declined by 44.06%, profits have increased by 13.2%, resulting in a PEG ratio of 1.2, which may reflect a valuation gap between earnings growth and market pricing.
Promoters remain the majority shareholders, maintaining significant control over the company’s strategic direction.
Holding Indo US Bio-Tech Ltd from Other Agricultural Products? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Comparative Performance and Market Position
Indo US Bio-Tech’s 52-week high was Rs.205.10, indicating that the current price level of Rs.104.85 represents a decline of nearly 49% from its peak. This substantial drop highlights the stock’s underperformance relative to the broader market and its sector peers.
Over the last three years, the stock has consistently underperformed the BSE500 index across multiple time horizons, including the last three months and one year. This trend points to challenges in sustaining growth momentum and market confidence.
The broader market environment has been turbulent, with the Sensex trading below its 50-day moving average, although the 50DMA remains above the 200DMA, suggesting some underlying support at longer-term levels. The elevated volatility in the market, as evidenced by the INDIA VIX reaching a 52-week high, has contributed to risk aversion among investors.
Summary of Key Metrics
To summarise, Indo US Bio-Tech Ltd’s recent fall to Rs.104.85 marks a significant technical low point amid a challenging market backdrop. The stock’s financial results have shown contraction in profits and sales in recent quarters, while long-term growth rates remain modest. Despite this, the company retains strong capital efficiency and manageable debt levels, with valuation metrics suggesting a discount relative to peers.
Market conditions remain volatile, with sectoral pressures and broader index weakness influencing the stock’s performance. Indo US Bio-Tech’s downgrade to a Sell rating by MarketsMOJO on 19 Jan 2026 reflects these factors, alongside its subdued returns and earnings trends.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
